Enovis Corp Stock Price, News & Analysis

Enovis Corporation (NYSE: ENOV) reported second quarter 2022 sales of $395 million, marking an 11% increase. Operating income stood at $6 million, with adjusted EBITDA rising 11% to $56 million. The net income was $121 million, equating to $2.21 per diluted share, while adjusted earnings per share surged 44% to $0.59. The company updated its full-year adjusted EBITDA outlook to $235-255 million, adjusting its EPS guidance to $2.15-$2.35 due to currency pressures and a tax benefit. Enovis recently acquired Insight Medical Systems and 360 Med Care, expanding its market reach and innovation.

Enovis (NYSE: ENOV) has launched its ARVIS (Augmented Reality Visualization and Information System), a groundbreaking AR technology aimed at orthopedic surgery. Over 200 successful cases in the U.S. demonstrate its application in enhancing the precision of hip and knee implant placements. Unlike traditional robotic systems, ARVIS is hands-free and reduces the need for extra staff, making it accessible to various surgical centers. This innovation is not only effective but also environmentally sustainable by eliminating single-use plastics.

Enovis Corporation (NYSE: ENOV) announced an investor conference call for its second quarter 2022 financial results, scheduled for August 4, 2022, at 8:00 AM ET. An earnings press release will be issued that morning, and a presentation will be available on the company's website. Investors can access the live webcast through the Enovis site or by calling (800) 715-9871 (U.S.) or (646) 307-1963 (International) with conference ID 1950250. A replay of the call will also be made available later the same day.

Enovis Corporation (NYSE: ENOV) has acquired Insight Medical Systems, enhancing its reconstructive portfolio with the FDA-cleared ARVIS® augmented reality surgical guidance technology. This acquisition aims to improve patient outcomes in hip and knee replacements. The ARVIS® system, already in use for over 200 cases in the U.S., offers real-time, hands-free guidance and is expected to be commercially available in Q3 2022. Enovis anticipates further growth and innovation by integrating this technology into its surgical business.

Enovis Corporation (NYSE: ENOV) announced the appointment of Ben Berry as the new Chief Financial Officer, effective January 1, 2023. Berry succeeds Chris Hix, who will transition to an advisory role until his retirement later in 2023. CEO Matt Trerotola praised Berry for his financial leadership and contributions to the company's growth strategy and improved operational performance since joining in 2020. Hix has played a pivotal role in transforming Enovis into a specialized medical technology leader since 2016.

Enovis Corporation (NYSE:ENOV) has unveiled the new Arsenal Ankle Plating System™, expanding its product line with 37 anatomically designed plates across nine families. This innovative system addresses both tri-malleolar and intra-articular fractures, enhancing the company's offerings in the ankle and foot market. The Arsenal System incorporates advanced technologies such as variable angle locking and multi-lock functionality to improve surgical outcomes. The launch reinforces Enovis' commitment to driving growth through differentiated medical solutions.

Enovis Corporation (NYSE: ENOV) will participate in the Goldman Sachs 43rd Annual Global Healthcare Conference on June 13, 2022. CEO Matt Trerotola and CFO Chris Hix will engage with investors at the event in Rancho Palos Verdes, California. The company, previously known as Colfax Corporation, focuses on innovative medical technology aimed at improving patient outcomes and transforming healthcare workflows.

For more details, visit www.enovis.com.

Enovis Corporation (NYSE: ENOV) reported strong first-quarter 2022 results, with sales of $375 million, a 21% increase year-over-year, and 7% organic growth. Reconstructive sales surged 72% to $131 million, while Prevention and Recovery sales rose 4% to $245 million. Adjusted EBITDA grew 25% to $48 million, with a margin of 12.7%. After spinning off ESAB Corporation, Enovis now has no net leverage. The company maintains its full-year guidance, projecting revenue growth of 10% to 14% and adjusted EPS of $2.20 to $2.40.

Enovis Corporation (NYSE: ENOV), an innovative medical technology company, announced it will release pro forma financial results for Q1 FY2022 on May 10, 2022. A public conference call will follow at 8:00 a.m. Eastern, where company officials will discuss the results. Interested parties can join the call by phone or through a webcast on Enovis’ website. The event aims to provide insights into the company's performance and strategies for growth.